Concepedia

Greg Dueck

GD

Statistics

Publications

8

Citations

498

H-Index

8

Active since

2009

Affiliations

BC Cancer Agency(Current)

University of Alberta

Saint John Regional Hospital

University of Calgary

Georgetown University

Greg Dueck is an author at BC Cancer Agency specializing in medicine, oncology, and immunotherapy.

ORCID

Publications per year

2009–2020

8

Publications

8

Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study

Bruce D. Cheson, Neil Chua, Greg Dueck et al. · Journal of Clinical Oncology · 2018 · 167 citations · Full text

, , +14

Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T‐cell lymphoma

Ethan Toumishey, Angeli Prasad, Greg Dueck et al. · Cancer · 2014 · 105 citations · Full text

, , +16

Interim report of a phase 2 clinical trial of lenalidomide for T‐cell non‐Hodgkin lymphoma

Greg Dueck, Neil Chua, Angeli Prasad et al. · Cancer · 2010 · 99 citations · Full text

, , +16

Obinutuzumab plus Bendamustine Followed by Obinutuzumab Maintenance Prolongs Overall Survival Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Updated Results of the GADOLIN Study

Bruce D. Cheson, Marek Trněný, Kamal Bouabdallah et al. · Blood · 2016 · 49 citations

, , +9

Activity of lenalidomide in a phase II trial for T-cell lymphoma: Report on the first 24 cases

Greg Dueck, Neil Chua, Angeli Prasad et al. · Journal of Clinical Oncology · 2009 · 27 citations

, , +12

1–5 of 8